Navigation Links
Orexigen(R) Therapeutics Announces Fourth Quarter and Year Ended December 31, 2009 Financial Results
Date:3/9/2010

lities 1,258 1,767 Commitments and contingencies Stockholders’ equity: Preferred stock, $.001 par value, 10,000,000 shares authorized at December 31, 2009 and 2008; no shares issued and outstanding at December 31, 2009 and 2008 - - Common stock, $.001 par value, 100,000,000 shares authorized at December 31, 2009 and 2008; 47,215,479 and 34,433,322 shares issued and outstanding at December 31, 2009 and 2008, respectively 47 34 Additional paid-in capital 342,599 253,782 Accumulated other comprehensive income (loss) (6) 153 Deficit accumulated during the development stage (266,737) (200,175) -------- -------- Total stockholders’ equity 75,903 53,794 ------ ------ Total liabilities and stockholders’ equity $96,848 $91,908 ======= =======
'/>"/>
SOURCE Orexigen Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

Related medicine technology :

1. Orexigen(R) Initiates Second Phase IIb Empatic(TM) Trial on Schedule
2. Orexigen(R) Therapeutics Presents Data on Its Proprietary Formulation of Naltrexone Sustained Release (SR) Used in Contrave(R)
3. Orexigen(R) Therapeutics Announces Changes to Its Clinical Programs and Management Team
4. Orexigen(R) Therapeutics Schedules July 20, 2009 Teleconference and Webcast Discussion of Contrave(R) Phase 3 Results
5. Orexigen(R) Therapeutics Schedules September 30, 2009 Teleconference and Webcast to Discuss Phase 2b Trial Results From Second Obesity Drug Candidate, Empatic(TM)
6. Orexigen(R) Therapeutics Releases New Efficacy Data for Contrave(R) in Late Breaker Presentations at the 27th Annual Scientific Meeting of The Obesity Society
7. Orexigen(R) Therapeutics Announces Third Quarter 2009 Financial Results
8. Orexigen(R) Therapeutics to Speak at Lazard Capital Markets Healthcare Conference
9. Orexigen(R) Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635
10. Orexigen(R) Therapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
11. Orexigen(R) Therapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/15/2014)... Research and Markets ( http://www.researchandmarkets.com/research/32cmct/inferior_vena ) ... Cava (IVC) Filters - Global Trends, Estimates and Forecasts, ... http://photos.prnewswire.com/prnh/20130307/600769 Global Inferior Vena ... million by 2016. The North America ... value while Europe claims approximately ...
(Date:12/15/2014)... BRIDGEWATER, N.J. , Dec. 15, 2014 ... US (EURONEXT: SAN and NYSE: SNY) are collaborating with ... Cholesterol Counts , an awareness program that will ... and the risks associated with high LDL-C (bad cholesterol). ... .com to take a brief poll and answer ...
(Date:12/15/2014)... --  DaVita HealthCare Partners Inc.  (NYSE: ... most innovative health care communities, today announced that ... Research  (DCR) and  HealthCare Partners Clinical Research , will ... research and data analytics services, specifically in patients ... disease (ESRD), as well as primary care and ...
Breaking Medicine Technology:Inferior Vena Cava (IVC) Filters - Global Trends, Estimates and Forecasts, 2012-2018 2Inferior Vena Cava (IVC) Filters - Global Trends, Estimates and Forecasts, 2012-2018 3Inferior Vena Cava (IVC) Filters - Global Trends, Estimates and Forecasts, 2012-2018 4Have You Been Counted? Regeneron and Sanofi US Join Forces with Leading Cardiovascular Organizations to Raise Awareness of Cholesterol 2Have You Been Counted? Regeneron and Sanofi US Join Forces with Leading Cardiovascular Organizations to Raise Awareness of Cholesterol 3Have You Been Counted? Regeneron and Sanofi US Join Forces with Leading Cardiovascular Organizations to Raise Awareness of Cholesterol 4Have You Been Counted? Regeneron and Sanofi US Join Forces with Leading Cardiovascular Organizations to Raise Awareness of Cholesterol 5Have You Been Counted? Regeneron and Sanofi US Join Forces with Leading Cardiovascular Organizations to Raise Awareness of Cholesterol 6DaVita Clinical Research and HealthCare Partners Clinical Research to Merge and Expand Clinical Trials and Data Analytics Capabilities 2DaVita Clinical Research and HealthCare Partners Clinical Research to Merge and Expand Clinical Trials and Data Analytics Capabilities 3DaVita Clinical Research and HealthCare Partners Clinical Research to Merge and Expand Clinical Trials and Data Analytics Capabilities 4
... Incorporated (Nasdaq: VPHM ) today announced that ... of the European Medicines Agency (EMA) has adopted a ... Authorization (PUMA) for Buccolam® (midazolam, oromucosal solution), for treatment ... and adolescents, from 3 months to less than 18 ...
... serving Virginia patients reduced healthcare-acquired infection rates (HAIs) a ... of $1.2 million in additional costs to the health ... existing federal hand washing protocols, these hospitals improved patient ... patient length-of-stay and unnecessary readmissions. VHHA Services, ...
Cached Medicine Technology:ViroPharma Announces Positive CHMP Opinion for Buccolam® (Midazolam, Oromucosal Solution) in the European Union 2ViroPharma Announces Positive CHMP Opinion for Buccolam® (Midazolam, Oromucosal Solution) in the European Union 3ViroPharma Announces Positive CHMP Opinion for Buccolam® (Midazolam, Oromucosal Solution) in the European Union 4ViroPharma Announces Positive CHMP Opinion for Buccolam® (Midazolam, Oromucosal Solution) in the European Union 5Virginia Hospitals Reduce Infections 41% 2Virginia Hospitals Reduce Infections 41% 3
(Date:12/17/2014)... December 17, 2014 Dr. Myo Nwe is ... Loss Diet of the Future” and co-founder of the Ace ... book, Dr. Nwe takes a broad look at the industry ... up under scientific scrutiny. On film and in television shows, ... mostly toward the social aspects and played for basic laughs, ...
(Date:12/17/2014)... (PRWEB) December 17, 2014 HeartMath® ... authorities on stress, heart rate variability (HRV), heart ... licensing its extensive HRV databases and algorithms to ... opportunities will enable HeartMath’s partners to offer its ... extensive research, as well as its normative HRV ...
(Date:12/17/2014)... December 17, 2014 No matter how ... able to eradicate the head louse parasite—a common childhood ... parents. Each year between six and twelve million individuals ... Miami-based lice removal treatment company comes to the rescue, ... environmentally friendly. With its track record of customer service, ...
(Date:12/17/2014)... MONDAY, Dec. 15, 2014 (HealthDay News) -- As gas ... and deaths, a new study suggests. In times ... many of those riders are inexperienced, the researchers explained. ... in California, which has the highest number of motorcycle ... number of motorcyclist deaths. The analysis revealed a ...
(Date:12/17/2014)... 16, 2014 (HealthDay News) -- Poor students get more fruits ... new study finds. But, the opposite is true for ... fruits and vegetables at school may give a healthy boost ... no matter what the family income level, students all ate ... study found. The study was published recently in the ...
Breaking Medicine News(10 mins):Health News:Obesity Should Not Be a Hollywood Punchline, Weight Loss Doc Says 2Health News:HeartMath® Inc.’s HRV Platform Solutions Available for Licensing 2Health News:HeartMath® Inc.’s HRV Platform Solutions Available for Licensing 3Health News:Lice Troopers Announces New Lice Treatment Clinic in Coral Gables to Service Key Biscayne, Coconut Grove, Kendall, Brickell & South Miami 2Health News:When Gas Prices Go Up, So Do Motorcycle Accidents, Study Finds 2Health News:Poor Students Eat Healthier Foods at School, Study Finds 2
... , WEDNESDAY, Nov. 17 (HealthDay News) -- Diabetics may ... is just a cell phone screen away. Researchers ... phone monitoring system that automatically picks up patients, home ... via radio signals from monitoring equipment outfitted with Blue-tooth ...
... mysterious culprit that threatens headaches, stuffy noses, skin rash ... people worldwide drink wine. The discovery could help winemakers ... and whites with less potential to trigger allergy symptoms, ... Journal of Proteome Research . Giuseppe ...
... WEDNESDAY, Nov. 17 (HealthDay News) -- The U.S. Food and ... that their products are illegal. In warning letters to ... malt beverages is an "unsafe food additive," and the companies ... does not find support for the claim that the addition ...
... not been high on the list of targets for treating ... the development of neurodegenerative diseases than has been realized. ... the pericyte in a surprising new role as a key ... brain tissue from harmful substances. By manipulating pericyte levels, scientists ...
... News) -- Get ready, get set, quit! Thursday marks ... which urges all smokers to lay off the habit for at ... about smoking and a large decrease in smoking rates since the ... local and nationwide events meant to encourage smokers to quit for ...
... 17, 2010) HealthGrades, the nation,s leading independent ... patients a list of those hospitals with the ... receiving a donor organ. HealthGrades annual evaluation of ... clinical quality data, based on patient outcomes, for ...
Cached Medicine News:Health News:Cell Phone 'Telemonitoring' May Help Control Blood Pressure 2Health News:Cell Phone 'Telemonitoring' May Help Control Blood Pressure 3Health News:FDA Cracks Down on Caffeinated Alcohol Drinks 2Health News:FDA Cracks Down on Caffeinated Alcohol Drinks 3Health News:The pericyte becomes a player in Alzheimer's, other diseases 2Health News:The pericyte becomes a player in Alzheimer's, other diseases 3Health News:The pericyte becomes a player in Alzheimer's, other diseases 4Health News:Smokers Urged to Join Thursday's Great American Smokeout 2Health News:Nation's top hospital organ transplant centers identified by HealthGrades 2
Compression Bra...
Post-Surgical compression garments...
... The Albumin Cobalt Binding (ACB®) Test is ... Modified Albumin (IMA®) by measuring the cobalt ... serum sample. First identified in the early ... comes in contact with ischemic tissue in ...
... Test is a clinical chemistry assay that ... the cobalt binding capacity of albumin in ... the early 1990s, IMA is produced when ... tissue in the heart. During ischemia, the ...
Medicine Products: